The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
Open accessAbstract
The N -methyl- d -aspartate receptor hypofunction is one of the most prevalent models of schizophrenia. For example, healthy subjects treated with uncompetitive N -methyl- d -aspartate receptor antagonists elicit positive, negative, and cognitive-like symptoms of schizophrenia. Patients with anti- N -methyl- d -aspartate receptor encephalitis, which is likely caused by autoantibody-mediated down-regulation of cell surface N -methyl- d -aspartate receptors, often experience psychiatric symptoms similar to schizophrenia initially. However, where and when N -methyl- d -aspartate receptor hypofunction occurs in the brain of schizophrenic patients is poorly understood. Here we review the findings from N -methyl- d- aspartate receptor antagonist and autoantibody models, postmortem studies on N -methyl- d -aspartate receptor subunits, as well as the global and cell-type-specific knockout mouse models of subunit GluN1. We compare various conditional GluN1 knockout mouse strains, focusing on the onset of N -methyl- d -aspartate receptor deletion and on the cortical cell-types. Based on these results, we hypothesize that N -methyl- d -aspartate receptor hypofunction initially occurs in cortical GABAergic neurons during early postnatal development. The resulting GABA neuron maturation deficit may cause reduction of intrinsic excitability and GABA release, leading to disinhibition of pyramidal neurons. The cortical disinhibition in turn could elicit glutamate spillover and subsequent homeostatic down regulation of N -methyl- d -aspartate receptor function in pyramidal neurons in prodromal stage. These two temporally-distinct N -methyl- d -aspartate receptor hypofunctions may be complimentary, as neither alone may not be able to fully explain the entire schizophrenia pathophysiology. Potential underlying mechanisms for N -methyl- d -aspartate receptor hypofunction in cortical GABA neurons are also discussed, based on studies of naturally-occurring N -methyl- d -aspartate receptor antagonists, neuregulin/ErbB4 signaling pathway, and theoretical analysis of excitatory/inhibitory balance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has thus been postulated that the NMDA hypofunction in SZ mainly occurs in cortical GABAergic interneurons 165.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [165]
Experimental — accuracy not yet measuredIn the citing paper
“There is strong support for NMDA hypofunction in SZ, as treatment with NMDAR antagonists, such as MK-801 or phencyclidine, can induce SZ-like symptoms in both human subjects 165 and in animals 166.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Parvalbumin neurons and gamma rhythms enhance cortical circuit performance
Sohal, V. S., Zhang, F., Yizhar, O., & Deisseroth, K. (2009) · Nature · doi:10.1038/nature07991 · Cited by 2,606 · cited 1×
“More importantly, induction of gamma oscillation driven by PV neuron-selective optogenetic activation was impaired in the mutants,(112) which strongly supports the idea that PV neuron is necessary for generation of gamma-band oscillations.(113,114) Notably, baseline gamma power increase and sensory-evoked gamma oscill…”
Driving fast-spiking cells induces gamma rhythm and controls sensory responses
Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., & Moore, C. I. (2009) · Nature · doi:10.1038/nature08002 · Cited by 2,603 · cited 1×
“More importantly, induction of gamma oscillation driven by PV neuron-selective optogenetic activation was impaired in the mutants,(112) which strongly supports the idea that PV neuron is necessary for generation of gamma-band oscillations.(113,114) Notably, baseline gamma power increase and sensory-evoked gamma oscill…”
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis
Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70253-2 · Cited by 2,435 · cited 1×
“Clinical expression of this disease consists of a variable presentation of psychiatric symptoms such as hallucinations, delusions, mania, catatonia, and insomnia days after the prodromal phase.(38) About 65% of adults first present with psychiatric symptoms and the majority are initially assessed by the psychiatric se…”
BackgroundThe essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory.
Tsien, J. Z., Huerta, P. T., & Tonegawa, S. (1996) · Cell · doi:10.1016/s0092-8674(00)81827-9 · Cited by 1,782 · cited 2×
“Spatial reference memory in Morris water maze test is intact in PV-cre/GluN1 KO mice(112) but is severely impaired in αCaMKII promoter-driven GluN1 knockout mice.(101) It is plausible that cognitive decline observed in a subtype of chronic patients may be explained by NMDAR hypofunction in cortical pyramidal neurons.”
BackgroundMethodJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Gresa-Arribas, N., Titulaer, M. J., Torrents, A., Aguilar, E., McCracken, L., Leypoldt, F., Gleichman, A. J., Balice-Gordon, R., Rosenfeld, M. R., Lynch, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70282-5 · Cited by 1,306
Cited by
Yan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“There is strong support for NMDA hypofunction in SZ, as treatment with NMDAR antagonists, such as MK-801 or phencyclidine, can induce SZ-like symptoms in both human subjects [165] and in animals [166].”
BackgroundThe origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Self-citationNMDA receptor functions in health and disease: Old actor, new dimensions
Dupuis, J. P., Nicole, O., & Groc, L. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.002 · Cited by 172
NMDAR Hypofunction Animal Models of Schizophrenia
Lee, G., & Zhou, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00185 · Cited by 160
Structural insights into the functional roles of 14-3-3 proteins
Obšilová, V., & Obšil, T. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1016071 · Cited by 143
“These studies have suggested that stabilizing the interaction between NMDARs and 14-3-3 proteins may be an efficient therapeutic approach because NMDAR hypofunction triggers symptoms of schizophrenia and its associated behaviors (reviewed in (Nakazawa et al., 2017)).”
Background
Metadata
- Authors
- Nakazawa, K., Jeevakumar, V., & Nakao, K.
- Affiliations
- University of Alabama at Birmingham (US)
- Corresponding author
- Nakazawa, Kazu
- Venue
- npj Schizophrenia
- Published
- 2017-02-03
- Volume
- 3
- Issue
- 1
- Pages
- 7-7
- ISSN
- 2334-265X (ISSN-L)
- PMC
- PMC5441533
- OpenAlex
- W2580207551
- Cited by
- 110
- References
- 147
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 9 · 2023: 15 · 2022: 10 · 2021: 14 · 2020: 13 · 2019: 12 · 2018: 14 · 2017: 4
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Schizophrenia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R01MH110681, K22MH099164)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- NMDA receptor hypofunction, anti-NMDA receptor encephalitis, glutamate spillover, excitation-inhibition balance, postnatal development, prodromal schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. https://app.cochat.ai/papers/10.1038/s41537-016-0003-3
- The paper
- Nakazawa, K., Jeevakumar, V., & Nakao, K. (2017). Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. npj Schizophrenia. https://doi.org/10.1038/s41537-016-0003-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.